Avidity Biosciences, Inc. (RNA)
RNA Stock Price Chart
Explore Avidity Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze RNA price movements and trends.
RNA Company Profile
Discover essential business fundamentals and corporate details for Avidity Biosciences, Inc. (RNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jun 2020
Employees
391.00
CEO
Sarah Boyce
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
RNA Financial Timeline
Browse a chronological timeline of Avidity Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.11, while revenue estimate is $1.93M.
Earnings released on 7 Aug 2025
EPS came in at -$1.21 falling short of the estimated -$0.95 by -27.37%, while revenue for the quarter reached $3.85M , beating expectations by +128.88%.
Earnings released on 8 May 2025
EPS came in at -$0.90 falling short of the estimated -$0.88 by -2.27%, while revenue for the quarter reached $1.57M , missing expectations by -40.07%.
Earnings released on 27 Feb 2025
EPS came in at -$0.80 falling short of the estimated -$0.76 by -5.26%, while revenue for the quarter reached $2.97M , beating expectations by +1.64%.
Earnings released on 7 Nov 2024
EPS came in at -$0.65 surpassing the estimated -$0.71 by +8.45%, while revenue for the quarter reached $2.34M , missing expectations by -45.29%.
Earnings released on 9 Aug 2024
EPS came in at -$0.65 surpassing the estimated -$0.76 by +14.47%, while revenue for the quarter reached $2.05M , missing expectations by -22.54%.
Earnings released on 9 May 2024
EPS came in at -$0.79 surpassing the estimated -$0.81 by +2.47%, while revenue for the quarter reached $3.54M , beating expectations by +38.40%.
Earnings released on 28 Feb 2024
EPS came in at -$0.79 falling short of the estimated -$0.54 by -46.30%, while revenue for the quarter reached $2.19M , missing expectations by -82.04%.
Earnings released on 8 Nov 2023
EPS came in at -$0.71 surpassing the estimated -$0.76 by +6.58%, while revenue for the quarter reached $2.82M , beating expectations by +27.51%.
Earnings released on 8 Aug 2023
EPS came in at -$0.66 surpassing the estimated -$0.84 by +21.43%, while revenue for the quarter reached $2.32M , beating expectations by +8.22%.
Earnings released on 9 May 2023
EPS came in at -$0.74 surpassing the estimated -$0.90 by +17.78%, while revenue for the quarter reached $2.23M , beating expectations by +9.46%.
Earnings released on 28 Feb 2023
EPS came in at -$0.88 falling short of the estimated -$0.84 by -4.76%, while revenue for the quarter reached $2.77M , beating expectations by +28.19%.
Earnings released on 8 Nov 2022
EPS came in at -$0.82 surpassing the estimated -$0.97 by +15.46%, while revenue for the quarter reached $2.48M , beating expectations by +16.80%.
Earnings released on 9 Aug 2022
EPS came in at -$0.92 falling short of the estimated -$0.74 by -24.32%, while revenue for the quarter reached $2.18M , beating expectations by +3.10%.
Earnings released on 10 May 2022
EPS came in at -$0.71 surpassing the estimated -$0.94 by +24.47%, while revenue for the quarter reached $1.80M , missing expectations by -5.53%.
Earnings released on 1 Mar 2022
EPS came in at -$0.82 falling short of the estimated -$0.73 by -12.33%, while revenue for the quarter reached $1.85M , missing expectations by -14.85%.
Earnings released on 9 Nov 2021
EPS came in at -$0.68 falling short of the estimated -$0.63 by -7.94%, while revenue for the quarter reached $2.16M , beating expectations by +15.67%.
Earnings released on 9 Aug 2021
EPS came in at -$0.70 surpassing the estimated -$0.77 by +9.09%, while revenue for the quarter reached $2.61M , meeting expectations.
Earnings released on 12 May 2021
EPS came in at -$0.64 falling short of the estimated -$0.52 by -23.08%, while revenue for the quarter reached $2.70M , beating expectations by +16.67%.
Earnings released on 15 Mar 2021
EPS came in at -$0.43 falling short of the estimated -$0.34 by -26.47%, while revenue for the quarter reached $2.14M .
Earnings released on 10 Nov 2020
EPS came in at -$0.31 surpassing the estimated -$0.32 by +3.13%, while revenue for the quarter reached $1.75M .
RNA Stock Performance
Access detailed RNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.